Perspective · 19 Mar 2025
Conference abstractPublished 28 Jul 2016
Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells
Sichuan University, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Human umbilical endothelial cells (HUVECs) have been proven to be effective in tumor anti-angiogenesis but the mechanism remained to be further demonstrated. The restricted ability of HUVECs to proliferate in vitro also limits their application on a large scale. In the present study, we immortalized HUVECs with hTERT genes by lentiviral infection and explored the antitumor immunity of hTERT-expressing HUVECs (HUVEC-TERTs). Results showed that HUVEC-TERTs presented high telomerase activity at both mRNA and protein levels by RT-PCR and TRAP-ELISA. They were proliferative after 70 PDs and expressed endothelial markers of CD31, VE-Cadherin, and VEGFR-II and integrin Ã?±5. They formed vascular tubes on matrigel at passage 30 without showing signs of senescence. Mice vaccinated with HUVEC-TERTs or HUVECs suffered smaller tumor volumes and survived longer than NS group both protectively and therapeutically. Compared with NS group; both groups revealed lower densities of CD34+ micro vessels in tumors, decreased concentrations of immune suppressors of TGF-Ã?² and VEGF in sera and elevated tilters of HUVECsneutralizing IgG. Cellular immunity was enhanced as specific CTL response against HUVECs was presented and larger percentages of CD8+CD69+ and CD8+IFN-Ã?³+ spleen T cells were detected by flow cytometry. In tumor microenvironment, the infiltration of CD4+ and CD8+ T cells were increased while MDSCs and Tregs were diminished in tumor tissues of both groups. In conclusion, this study was the first to confirm the anti-tumor immunity of irradiated hTERT-immortalized HUVECs. It might be a new strategy to allow HUVECs to be applied on a large scale as a cancer vaccine.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunotherapy: Open Access.
Perspective · 19 Mar 2025
Advancing Immunotherapy: Future Directions in the Fight against Renal Cell Carcinoma
Short communication · 19 Mar 2025
Emerging Therapies: The Latest Developments in Autoimmune Disease Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunotherapy: Open Access
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Xiyan Mu”
